{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T23:12:40Z","timestamp":1761606760870,"version":"build-2065373602"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,12]],"date-time":"2022-12-12T00:00:00Z","timestamp":1670803200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","award":["324730_192449"],"award-info":[{"award-number":["324730_192449"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Chromatography B"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.jchromb.2022.123575","type":"journal-article","created":{"date-parts":[[2022,12,12]],"date-time":"2022-12-12T11:29:34Z","timestamp":1670844574000},"page":"123575","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Development and validation of a liquid chromatography coupled to tandem mass spectrometry method for the monitoring of temsavir plasma concentrations in people living with HIV"],"prefix":"10.1016","volume":"1214","author":[{"given":"Paul","family":"Thoueille","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrich","family":"Seybold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurent A.","family":"Decosterd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Desfontaine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"unstructured":"World Health Organization (WHO). HIV Key facts. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hiv-aids (accessed 25 October 2022).","key":"10.1016\/j.jchromb.2022.123575_b0005"},{"key":"10.1016\/j.jchromb.2022.123575_b0010","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1093\/jac\/dkx042","article-title":"Prevalence of HIV-1 drug resistance in treated patients with viral load >50 copies, mL: a 2014 French nationwide study","volume":"72","author":"Assoumou","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.jchromb.2022.123575_b0015","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.cmi.2017.06.014","article-title":"Longitudinal trends of HIV drug resistance in a large Canadian cohort, 1996\u20132016","volume":"24","author":"Rocheleau","year":"2018","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.jchromb.2022.123575_b0020","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1093\/cid\/ciw128","article-title":"Emergence of Acquired HIV-1 Drug Resistance Almost Stopped in Switzerland: A 15-Year Prospective Cohort Analysis","volume":"62","author":"Scherrer","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.jchromb.2022.123575_b0025","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(17)33095-7","article-title":"Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies","volume":"391","author":"Llibre","year":"2018","journal-title":"Lancet (London, England)"},{"issue":"11","key":"10.1016\/j.jchromb.2022.123575_b0030","doi-asserted-by":"crossref","first-page":"e1003421","DOI":"10.1371\/journal.pmed.1003421","article-title":"Efficacy and safety of dolutegravir plus emtricitabine versus standard ART for the maintenance of HIV-1 suppression: 48-week results of the factorial, randomized, non-inferiority SIMPL'HIV trial","volume":"17","author":"Sculier","year":"2020","journal-title":"PLoS Med."},{"key":"10.1016\/j.jchromb.2022.123575_b0035","article-title":"VIH H\u00e9patites virales Sant\u00e9 sexuelle","author":"Katlama","year":"2020","journal-title":"EDP Sci."},{"unstructured":"European AIDS Clinical Society (EACS) Guidelines. Version 11.1. October 2022.","key":"10.1016\/j.jchromb.2022.123575_b0040"},{"key":"10.1016\/j.jchromb.2022.123575_b0045","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1007\/s11904-020-00486-2","article-title":"Novel Antiretroviral Agents","volume":"17","author":"Cambou","year":"2020","journal-title":"Curr. HIV\/AIDS Rep."},{"key":"10.1016\/j.jchromb.2022.123575_b0050","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1002\/jps.23476","article-title":"Compartmental absorption modeling and site of absorption studies to determine feasibility of an extended-release formulation of an HIV-1 attachment inhibitor phosphate ester prodrug","volume":"102","author":"Brown","year":"2013","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jchromb.2022.123575_b0055","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1080\/14656566.2021.1937120","article-title":"Evaluating fostemsavir as a therapeutic option for patients with HIV","volume":"22","author":"Berruti","year":"2021","journal-title":"Expert Opin. Pharmacother."},{"issue":"8","key":"10.1016\/j.jchromb.2022.123575_b0060","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1080\/14787210.2021.1865801","article-title":"Fostemsavir for the treatment of HIV","volume":"19","author":"Seval","year":"2021","journal-title":"Expert Rev. Anti Infect. Ther."},{"unstructured":"European Medicines Agency (EMA). RUKOBIA cpr pell ret 600 mg. Summary of the product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/rukobia-epar-product-information_fr.pdf (accessed 25 October 2022).","key":"10.1016\/j.jchromb.2022.123575_b0065"},{"key":"10.1016\/j.jchromb.2022.123575_b0070","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1093\/ajhp\/zxaa416","article-title":"Fostemsavir: The first oral attachment inhibitor for treatment of HIV-1 infection","volume":"78","author":"Chahine","year":"2021","journal-title":"Am. J. Health Syst. Pharm."},{"unstructured":"European Medicines Agency (EMA). Assessment report. Rukobia. https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/rukobia-epar-public-assessment-report_en.pdf (accessed 28 October 2022).","key":"10.1016\/j.jchromb.2022.123575_b0075"},{"unstructured":"European Medicines Agency, Guideline on bioanalytical method validation. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2011\/08\/WC500109686.pdf, 2011 (accessed 11 March 2022).","key":"10.1016\/j.jchromb.2022.123575_b0080"},{"unstructured":"U.S. Food and Drug Administration, Guidance for industry: bioanalytical method validation. https:\/\/www.fda.gov\/files\/drugs\/published\/Bioanalytical-Method-Validation-Guidance-for-Industry.pdf, 2018 (accessed 11 March 2022).","key":"10.1016\/j.jchromb.2022.123575_b0085"},{"unstructured":"Federal Act on Research involving Human Beings. Human Research Act, HRA. https:\/\/www.admin.ch\/opc\/en\/classified-compilation\/20061313\/index.html#a2 (accessed 25 October 2022).","key":"10.1016\/j.jchromb.2022.123575_b0090"},{"key":"10.1016\/j.jchromb.2022.123575_b0095","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1002\/(SICI)1097-0231(19990630)13:12<1175::AID-RCM639>3.0.CO;2-0","article-title":"The effects of sample preparation methods on the variability of the electrospray ionization response for model drug compounds","volume":"13","author":"Bonfiglio","year":"1999","journal-title":"Rapid Commun. Mass Spectromet.: RCM"},{"key":"10.1016\/j.jchromb.2022.123575_b0100","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1021\/ac020361s","article-title":"Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS\/MS","volume":"75","author":"Matuszewski","year":"2003","journal-title":"Anal. Chem."},{"key":"10.1016\/j.jchromb.2022.123575_b0105","first-page":"579","article-title":"Harmonization of strategies for the validation of quantitative analytical procedures. A SFSTP proposal\u2013Part I","volume":"36","author":"Hubert","year":"2004","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jchromb.2022.123575_b0110","first-page":"169","article-title":"M\u00e9thodes chromatographiques de dosage dans les milieux biologiques: strat\u00e9gie de validation. Rapport d'une commission SFSTP","volume":"7","author":"Chapuzet","year":"1997","journal-title":"STP Pharma Sci."},{"key":"10.1016\/j.jchromb.2022.123575_b0115","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/S0731-7085(03)00182-1","article-title":"An analysis of the SFSTP guide on validation of chromatographic bioanalytical methods: progress and limitations","volume":"32","author":"Boulanger","year":"2003","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jchromb.2022.123575_b0120","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.chroma.2007.03.111","article-title":"Analysis of recent pharmaceutical regulatory documents on analytical method validation","volume":"1158","author":"Rozet","year":"2007","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.jchromb.2022.123575_b0125","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.chroma.2007.03.102","article-title":"Using tolerance intervals in pre-study validation of analytical methods to predict in-study results. The fit-for-future-purpose concept","volume":"1158","author":"Rozet","year":"2007","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.jchromb.2022.123575_b0130","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1007\/s11095-007-9242-3","article-title":"A total error approach for the validation of quantitative analytical methods","volume":"24","author":"Hoffman","year":"2007","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jchromb.2022.123575_b0135","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.chroma.2007.02.021","article-title":"Validation of analytical methods based on accuracy profiles","volume":"1158","author":"Feinberg","year":"2007","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.jchromb.2022.123575_b0140","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1007\/s11095-007-9291-7","article-title":"Quantitative bioanalytical methods validation and implementation: best practices for chromatographic and ligand binding assays","volume":"24","author":"Viswanathan","year":"2007","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jchromb.2022.123575_b0145","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1007\/s00216-004-2791-y","article-title":"New advances in method validation and measurement uncertainty aimed at improving the quality of chemical data","volume":"380","author":"Feinberg","year":"2004","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/j.jchromb.2022.123575_b0150","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.chroma.2014.05.047","article-title":"Derivation of uncertainty functions from validation studies in biological fluids: application to the analysis of caffeine and its major metabolites in human plasma samples","volume":"1353","author":"Gassner","year":"2014","journal-title":"J. Chromatogr. A"},{"issue":"6","key":"10.1016\/j.jchromb.2022.123575_b0155","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1177\/1060028020962424","article-title":"Fostemsavir: A Novel Attachment Inhibitor for Patients With Multidrug-Resistant HIV-1 Infection","volume":"55","author":"Hiryak","year":"2021","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.jchromb.2022.123575_b0160","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.trac.2018.04.013","article-title":"From method validation to result assessment: established facts and pending questions","volume":"105","author":"Rudaz","year":"2018","journal-title":"TrAC Trends Anal. Chem."},{"key":"10.1016\/j.jchromb.2022.123575_b0165","doi-asserted-by":"crossref","DOI":"10.1128\/aac.02251-21","article-title":"Pharmacokinetics of Temsavir, the Active Moiety of the HIV-1 Attachment Inhibitor Prodrug, Fostemsavir, Coadministered with Cobicistat, Etravirine, Darunavir\/Cobicistat, or Darunavir\/Ritonavir with or without Etravirine in Healthy Participants","volume":"66","author":"Moore","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"unstructured":"Fostemsavir PK Fact Sheet. University of Liverpool. Prudced July 2021. https:\/\/liverpool-hiv-hep.s3.amazonaws.com\/prescribing_resources\/pdfs\/000\/000\/217\/original\/HIV_FactSheet_FTR_2021_Jul.pdf?1632406754 (accessed 24 October 2022).","key":"10.1016\/j.jchromb.2022.123575_b0170"}],"container-title":["Journal of Chromatography B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570023222004809?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570023222004809?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T23:10:31Z","timestamp":1761606631000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1570023222004809"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":34,"alternative-id":["S1570023222004809"],"URL":"https:\/\/doi.org\/10.1016\/j.jchromb.2022.123575","relation":{},"ISSN":["1570-0232"],"issn-type":[{"type":"print","value":"1570-0232"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development and validation of a liquid chromatography coupled to tandem mass spectrometry method for the monitoring of temsavir plasma concentrations in people living with HIV","name":"articletitle","label":"Article Title"},{"value":"Journal of Chromatography B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jchromb.2022.123575","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"123575"}}